Comparisons of treatment satisfaction and health-related quality of life in patients with rheumatoid arthritis treated with tofacitinib and adalimumab
Authors' conclusion
This study identified that tofacitinib shows higher treatment satisfaction in the convenience domain of TSQM rather than adalimumab
Study context
- Population
- Patients with rheumatoid arthritis (RA) in real-world settings, 21 university-based hospitals throughout Korea
- Participants
- 410 patients
- Exposure
- Tofacitinib vs adalimumab
- Outcome
- Treatment satisfaction (TSQM) and HRQoL (EQ-5D), self-reported
Methodological detailsnon-interventional, multicenter, propensity score methods (greedy matching and stabilized inverse probability of treatment weight (IPTW))
- Non-interventional
- Multicenter
- Propensity score methods (greedy matching and stabilized IPTW)
Main finding
As reported in the abstract
Treatment satisfaction (TSQM domains)
- Tofacitinib showed higher Treatment Satisfaction Questionnaire for Medication (TSQM) convenience domain than adalimumab in all three samples (unweighted, greedy matching, stabilized IPTW)
- No difference in TSQM effectiveness, side effects and global satisfaction domains
- Multivariable analysis showed consistent results in TSQM
Observational data: associations, not effects.
Further findings
EQ-5D-based health-related quality of life (HRQoL)
- No statistical difference between the two drug groups in all three samples
Original publication
Comparisons of treatment satisfaction and health-related quality of life in patients with rheumatoid arthritis treated with tofacitinib and adalimumab. Arthritis Res Ther. Published 27 April 2023. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →